Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the UBS Global Life Sciences Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
|UBS Global Life Sciences Conference|
|Ron Squarer, Chief Executive Officer|
|Thursday, September 20, 2012|
|8:30 a.m. Eastern Time|
|The Grand Hyatt New York, NY|
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to www.arraybiopharma.com.